复方桐叶烧伤油促进糖尿病足皮肤创面愈合及通过p38 MAPK信号通路调节糖尿病足大鼠皮肤组织AQP3表达

探讨复方桐叶烧伤油通过p38信号通路调节激酶（MAPK）信号通路对糖尿病足大鼠 皮肤组织水通道蛋白3表达的影响。方法 选取60只SD大鼠随机分为正常对照组（A组）、糖尿病足 溃疡组（B组）、复方桐叶烧伤油组（C组）、复方桐叶烧伤油+S B 2 0 3 5 8 0组（D组），各15只。 B组、C组、D组45只大鼠腹腔注射链脲佐菌素诱导糖尿病后构建糖尿病足溃疡模型；比较各组研究指 标。结果 C组创面愈合率显著高于B组，D组创面愈合率显著低于C组（P ＜0.001）；B组、C组、D组 组织中TNF -α、I L - 6、CRP水平均显著高于A组，C组组织中TNF -α、I L - 6、CRP水平均显 著低于B组，D组组织中TNF-α、IL-6、CRP水平显著高于C组（P ＜0.001）；B组、D组组织中 APQ3、p38蛋白表达量均低于A组（P ＜0.001）；C组组织中APQ3表达量低于A组（P ＜0.001），而 p38蛋白表达量显著高于B组，D组APQ3、p38蛋白表达量均极显著低于C组（P ＜0.001）。结论 复方 桐叶烧伤油促进糖尿病足皮肤创面愈合，通过激活p38 MAPK信号通路磷酸化上调糖尿病足大鼠皮肤组 织中APQ3表达。     

沙棘籽油软胶囊中4种生育酚的含量测定

目的 建立沙棘籽油软胶囊中4种生育酚的HPLC含量测定方法。方法 采用Agilent Poroshell 120 PFP色谱柱（4.6 mm×250 mm，4 μm），流动相为甲醇-水（94∶6），检测波长为294 nm，柱温为26 ℃，流速为0.9 mL•min^-1。结果 α-生育酚、β-生育酚、γ-生育酚和δ-生育酚分别在1.83～91.48、1.86～93.09、1.84～91.85、1.77～88.70 μg•mL^-1范围内呈良好的线性关系，平均回收率在96.32%～98.45%之间，RSD在0.48%～1.43%。结论 建立的方法重复性好，专属性强，能够用于测定沙棘籽油软胶囊中4种生育酚的含量。     

气相色谱-串联质谱法分析消瘤藤中挥发油成分

目的:研究消瘤藤中挥发油中的主要成分及其含量。方法:采用水蒸气蒸馏法提取消瘤藤的挥发油成分,用气相色谱-质谱联用技术进行测定,结合计算机检索技术对分离的化合物进行结构鉴定并用色谱峰面积归一化法获得各化合物的相对含量。结果:从消瘤藤中鉴定出27个成分,占挥发油总量的87.73%,相对含量较高的挥发油成分有棕榈酸(46.96%)、亚油酸(16.02%)、反油酸(5.12%)、顺-9-六癸酸(2.75%)、肉豆蔻酸(2.25%)、正十五酸(2.24%)。结论:本研究通过对消瘤藤挥发油成分的气相色谱-质谱联用分析,为其综合开发和利用提供科学依据。     

Lomustine’s nanoemulsion as nose-to-brain drug delivery system for CNS tumor treatment

Nose-to-brain delivery allows the direct targeting of drug molecules bypassing the Blood Brain Barrier and systemic effect. Nanoemulsion is one of the novel strategies to deliver drug in this route due to its simplicity in manufacturing, long-term stability, and strong solubilization property for drug. The anticancer drug lomustine had poor oral bioavailability in addition to its serious side effect, therefore, developing more effective drug delivery with direct targeting towards the brain through intra-nasal administration applying nanoemulsion technology is a promising alternative. The work involved lomustine solubility screening in oils, surfactants and cosurfactants as well as emulsifier ratio (Smix) nanoemulsion area was identified using pseudo-ternary phase diagrams. Eighteen nanoemulsion formulas were produced for optimization, then characterized for droplet size, polydispersity index, zeta potential, entrapment efficiency, conductivity, transmittance, dilution, visual transparency, physical stability and in vitro release. The optimum NE formula showed droplet size, zeta potential, polydispersity index, entrapment efficiency, %transmittance, conductivity of 31.31 nm, −30.65 mV, 0.159, 98.12%, 99.08%, and 951 us/cm, respectively. The best formula released 100% lomustine within 15 min which is a promising potential drug delivery system that may deliver the drug quickly and directly to the brain as a safe and effective alternative to oral delivery.     

鸦胆子油乳注射液联合CapeOx方案治疗早发型结肠癌的临床研究

目的 探讨鸦胆子油乳注射液联合CapeOx方案治疗早发型结肠癌的临床疗效。方法 选取2017年6月—2021年5月徐州医科大学附属连云港医院收治的96例早发型结肠癌患者，按随机数字表法将所有患者分为对照组和治疗组，每组各48例。对照组患者给予CapeOx方案化疗，化疗第1～14天餐后30 min口服卡培他滨片，1 g/m²，2次/d；第1天静脉滴注注射用奥沙利铂，130 mg/m²加入5%葡萄糖注射液250 mL中后给药，1次/d，每次滴注2 h。治疗组在对照组治疗基础上化疗第1～14天静脉滴注鸦胆子油乳注射液，30 mL/次加入0.9%氯化钠注射液250 mL中后给药，1次/d。两组均以21 d为1个周期，且均连续治疗2个周期。观察两组的临床疗效，比较治疗前后两组血清肿瘤标志物[癌胚抗原（CEA）、糖类抗原（CA）199、CA72-4、CA50]和血管内皮生长因子（VEGF）水平、大肠癌患者生命质量测定量表（FACT-C）评分。统计两组不良反应情况。结果 治疗后，治疗组客观缓解率（ORR）是47.92%，较对照组的35.42%有所提高，但差异无统计学意义；治疗组疾病控制率（DCR）是87.50%显著高于对照组的70.83%（P＜0.05）。治疗后，两组FACT-C中生理状况评分、情感状况评分、附加关注领域评分及量表总评分均显著增加（P＜0.05）；且均以治疗组患者增加更显著（P＜0.05）；功能状况和社会/家庭状况领域评分组内治疗前后及组间同期比较差异均无统计学意义。治疗后，两组血清CEA、CA199、CA72-4、CA50和VEGF水平均显著下降（P＜0.05）；均以治疗组降低更显著（P＜0.05）。治疗过程中，治疗组白细胞减少、肝肾损害、血小板减少的发生率分别为18.75%、10.42%、14.58%，显著低于对照组的37.50%、27.08%、33.33%（P＜0.05）。结论 鸦胆子油乳注射液联合CapeOx方案治疗早发型结肠癌具有一定的增效减毒作用，能有效提高患者近期疗效、下调血清肿瘤标志物水平及抑制肿瘤血管生成，并提高化疗耐受性，改善患者生命质量，值得临床推广应用。     

Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose–response meta-analysis of randomized controlled trials

IntroductionNumerous approaches have been assigned to treat dyslipidemia (DLP). Turmeric/curcumin have been widely investigated with this regard. In the current study, we explored the effect of curcumin/turmeric supplementation on lipid profile.MethodsOnline databases were searched up to October 2022. The outcomes included triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), apolipoprotein B (Apo-B), and apolipoprotein A (Apo-A). We used the Cochrane quality assessment tool to evaluate the risk of bias. The effect sizes were estimated as weighted mean difference (WMD) and 95% confidence intervals (CIs).ResultsOut of 4182 articles retrieved from the initial search, 64 randomized clinical trials (RCTs) were included in the study. Between-study heterogeneity was significant. Meta-analysis showed that turmeric/curcumin supplementation exerts statistically significant improvements on blood levels of TC (WMD = −3.99 mg/dL; 95% CI = −5.33, −2.65), TG (WMD = −6.69 mg/dL; 95% CI = −7.93, −5.45), LDL-c (WMD = −4.89 mg/dL; 95% CI = −5.92, −3.87), and HDL-c (WMD = 1.80 mg/dL; 95% CI = 1.43, 2.17). However, turmeric/curcumin supplementation was not associated with improvements in blood levels of Apo-A or Apo-B. The studies did not thoroughly address the issues of potency, purity, or consumption with other foods.ConclusionTurmeric/curcumin supplementation seems to be effective in improving blood levels of TC, TG, LDL-c, and HDL-c; but may not be capable of improving their pertinent apolipoproteins. Since the evidence was assessed to be low and very low concerning the outcomes, these findings should be dealt with caution.